Skip to main content

Table 3 Association of serum uromodulin with ESKD, cardiovascular events and all-cause mortality

From: Serum uromodulin and progression of kidney disease in patients with chronic kidney disease

Serum uromodulin tertiles (ng/mL) Model 1 Model 2 Model 3
HR (95% CI) HR (95% CI) HR (95% CI)
ESKD events
 > 100.8 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
 > 52.7–100.8 3.70 (2.48, 5.54) 3.23 (2.15, 4.85) 1.36 (0.90, 2.06)
 ≤ 52.7 10.46 (7.20, 15.21) 7.47 (5.06, 11.03) 1.92 (1.26, 2.90)
 Per SD increase 0.26 (0.21, 0.32) 0.31 (0.25, 0.38) 0.69 (0.55, 0.86)
Cardiovascular events
 > 100.8 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
 > 52.7–100.8 1.37 (0.92, 2.04) 1.04 (0.70, 1.56) 0.80 (0.52, 1.22)
 ≤ 52.7 1.85 (1.27, 2.70) 1.24 (0.83, 1.86) 0.81 (0.51, 1.28)
 Per SD increase 0.71 (0.59, 0.87) 0.88 (0.72, 1.08) 1.14 (0.89, 1.45)
All-cause mortality
 > 100.8 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
 > 52.7–100.8 1.63 (0.80, 3.29) 1.35 (0.65, 2.77) 1.04 (0.48, 2.23)
 ≤ 52.7 2.59 (1.34, 5.00) 1.94 (0.96, 3.94) 1.30 (0.58, 2.93)
 Per SD increase 0.63 (0.45, 0.89) 0.73 (0.51, 1.04) 0.92 (0.60, 1.41)
  1. Model 1: Adjusted for age, gender
  2. Model 2: Model 1+ current smoker, body-mass index, diabetes, systolic blood pressure, using anti-hypertensive medications in the past 2 weeks, cardiovascular diseases history, logarithm transformed triglyceride, logarithm transformed low-density lipoprotein cholesterol, prealbumin, logarithm transformed high-density lipoprotein cholesterol, logarithm transformed sensitive-reactive protein and logarithm transformed urinary albumin/creatinine ratio
  3. Model 3: Model 2+ estimated glomerular filtration rate
  4. ESKD end stage kidney disease, SD standard deviation